Arrowhead Pharmaceuticals宣布，其创新药物Redemplo®（Plozasiran）已获得澳大利亚治疗商品管理局（TGA）的批准。这一重要监管进展将显著提升家族性乳糜微粒血症综合征（FCS）患者在全球范围内的治疗可及性。
FCS是一种罕见的遗传性疾病，患者因脂蛋白脂肪酶功能缺陷导致严重高甘油三酯血症。Redemplo®作为一款靶向疗法，通过RNA干扰机制精准调控疾病相关基因表达，为患者提供了新的治疗选择。
此次TGA批准标志着Arrowhead Pharmaceuticals在亚太地区市场拓展的重要里程碑。公司致力于通过持续创新，为全球罕见病患者提供突破性治疗方案。该批准也将进一步巩固Arrowhead在代谢疾病治疗领域的领先地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.